Tesamorelin research library
Technical articles on Tesamorelin's structure, the analytical methods used to test it, and how to read and evaluate its documentation. Every article is dated, cites its sources and draws on the published lot data.
Last updated
Analytical methods
HPLC analysis of Tesamorelin: how purity is measured
How Tesamorelin purity is measured by reversed-phase HPLC-UV: retention time, main and secondary peaks, area normalization, results for every Tesamorelin lot, interpretation and method limits.
Tesamorelin purity: what a purity percentage does and doesn't tell you
What HPLC purity measures for Tesamorelin, how it differs from peptide content and net content, where impurities in synthetic peptides come from, and how to compare purity between lots and suppliers.
Editorial standards
Research library articles follow four rules:
- Sources are institutional. Citations are limited to NIH resources (NCBI Gene, PubChem, PubMed and PubMed Central) and U.S. FDA guidance.
- Our own data is labeled. Figures from Tesamorelin certificates are identified by lot, and calculations we perform, such as expected m/z values, are marked as ours.
- Limits are stated. Each article says what a method or document does not establish, not just what it does.
- Every article is dated. Published and updated dates appear at the top, and articles are revised when lot data or sources change. Changes are logged in research updates.
- Scope is analytical. Articles cover structure, chemistry, testing and documentation. They do not cover dosing, administration, protocols or medical advice.
Primary documentation
The research library explains the data; the data itself lives in the certificate of analysis archive, one page per lot.
For how testing is organized end to end, see Testing and quality. For quick answers, see the FAQ.
Buy Tesamorelin
10 mg vials. Current lot KB-77284 tested at 99.54% purity with identity confirmed by HPLC retention-time match against a reference standard. Current purchasing is available through Klow.bio.